Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Division of Cancer Genome Research

Prof. Dr. Holger Sültmann


The evolution of tumors is accompanied by molecular alterations on genomic, epigenomic, and gene expression levels. The aims of our research are to identify these molecular changes, to translate them into the diagnosis, prognosis and prediction of cancer, and to understand their roles in the formation and progression of tumors. Our research comprises the genome-wide analysis of molecular alterations in various cancer entities with an emphasis on lung and breast tumors. To this end, we apply high-throughput technologies for DNA- and RNA-sequencing in tissues and blood samples („liquid biopsy“) and use the identified molecular markers for individual risk stratification and personalized clinical management of patients based on the tumor heterogeneity in space and time. To understand the roles of these molecular alterations in tumor progression and therapy resistance, we apply cellular 3D-coculture models as well as a variety of cell- and molecular biology methods.


Prof. Dr. Holger Sültmann
Cancer Genome Research (B063)

Deutsches Krebsforschungszentrum und Deutsches Konsortium für Translationale Krebsforschung
Im Neuenheimer Feld 460
69120 Heidelberg

Tel: +49 (0)6221 565934
E-Mail: h.sueltmann (at)

Selected Publications

  • Janke F et al., Monitoring progression of ALK-rearranged lung adenocarcinoma using DNA methylation patterns in cell free DNA. Clinical Epigenetics 14(1):163, 2022
  • Angeles AK, Christopoulos P et al., Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis. NPJ Precision Oncology 5(1):100, 2021
  • Dietz S, Christopoulos P et al., Longitudinal therapy monitoring of ALK-positive non-small cell lung cancer by copy number profiling combined with targeted sequencing of cell-free DNA. EBioMedicine; 62: 103103, 2020
  • The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature 578(7793), 82-93, 2020
to top
powered by webEdition CMS